Advertisement
Canada markets open in 1 hour 27 minutes
  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CAD/USD

    0.7297
    -0.0004 (-0.06%)
     
  • CRUDE OIL

    81.29
    -0.61 (-0.74%)
     
  • Bitcoin CAD

    90,497.49
    +158.30 (+0.18%)
     
  • CMC Crypto 200

    1,417.57
    +2.81 (+0.20%)
     
  • GOLD FUTURES

    2,315.80
    -30.60 (-1.30%)
     
  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     
  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     
  • NASDAQ futures

    17,388.75
    +38.75 (+0.22%)
     
  • VOLATILITY

    16.63
    -0.31 (-1.83%)
     
  • FTSE

    8,044.96
    +21.09 (+0.26%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6833
    -0.0017 (-0.25%)
     

Eli Lilly stock dips after imposter account posts prank on Twitter

Shares of Eli Lilly ticked downward after a fake account posed as the company on Twitter.

Video Transcript

JARED BLIKRE: Eli Lilly, that is my pick of the day. Healthcare taking a backseat in today's rally, as defensive sectors lag. And here we go because guess what? This company, too, got caught up in the maelstrom. They're dealing with an impostor account on Twitter. And earlier, that impostor account said free insulin for all. This was false.

And the company is issuing a response, in which it reads, quote, "We apologize to those who have been served a misleading message from a fake Lilly account. Our official Twitter account is @lillypad." All of this is a microcosm of the chaos at Twitter as Elon Musk's push for Twitter Blue subscriptions hit a roadblock, to say the least, as we were just talking about, Dave, with Dan Howley.

ADVERTISEMENT

DAVE BRIGGS: Is there a fake Jared Blikre account out there with fake charts going on? You need to keep your eye on that.

JARED BLIKRE: I will. I will man that.

DAVE BRIGGS: I'm a big believer in Eli Lilly because of that Mounjaro, that diabetes weight loss drug, could be revolutionary. Fast track status from the FDA, so that you can, indeed, believe.